This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|June 25, 2009
Former Senate Leaders Support Follow-On Biologics Pathway, Comparative Effectiveness Research
Author(s)Angie Drakulich
Former Senator Majority Leaders Howard Baker, Tom Daschle, and Bob Dole released a report this month, Crossing Our Line: Working Together to Reform the US Health System, which proposes four pillars of health reform.
Advertisement
Former Senator Majority Leaders Howard Baker, Tom Daschle, and Bob Dole released a report this month, Crossing Our Line: Working Together to Reform the US Health System, which proposes four pillars of health reform. The pillars are: (1) Promoting High-Quality, High-Value Care; (2) Making Health Insurance Available, Meaningful and Affordable; (3) Emphasizing and Supporting Personal Responsibility and Healthy Choices; and (4) Developing a Workable and Sustainable Approach to Health Care Financing. The report comes out of the Bipartisan Policy Center, a nonprofit organization established in 2007 by Baker, Daschle, Dole, and former Senator George Mitchell to provide a forum for discussing tough policy challenges.
Specific recommendations under Pillar 1 that may be of interest to the pharmaceutical industry include moving to electronic, patient-centered quality reporting, and expanding comparative effectiveness research (e.g., developing the infrastructure to compare treatment and practices, and prioritizing research topics). Pillar 4 recommendations are also noteworthy, including the suggestion to create an approval pathway for competing biologic products (i.e., follow-on biologics).
The report suggests that Congress create such a regulatory pathway in order to promote competition, and thus, save significant costs for individuals and for federal programs (specifically, $9 billion over 10 years, says the report). The authors specifically state their support for the bipartisan legislation in both the House and Senate on this matter, and suggest Congressional leaders “resolve policy differences” regarding exclusivity “in time to pass this legislation as a component of healthcare reform.”
Read the
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement